Alicia Morgans, MD, MPH provides insight on the treatment of mCRPC with lutetium-177-PSMA-617 in recurrent setting.
EP. 1: Case Overview: A 70-Year-Old Man with Metastatic Castration-Resistant Prostate Cancer
Alicia Morgans, MD, MPH presents the case of a 70-year-old man with progressive PSMA-positive mCRPC.
EP. 2: First-line Treatment Options for mCRPC
Dr. Morgans discusses first-line therapy options for mCRPC and her approach to deciding between different treatment options.
EP. 3: Follow-up and Monitoring
An overview of how patients with mCRPC are monitored and followed-up in practice and the triggers to reevaluate the treatment patient is receiving.
EP. 4: Second-line and Beyond: Treatment of mCRPC
Dr. Morgans talks about available second-line treatment options for patients with mCRPC and considerations when choosing second and subsequent-line treatment options.
EP. 5: VISION Study
A review of the data from phase 3 randomized Phase 3 Study of 177Lu-PSMA-617 or best supportive/standard of care, VISION, in the treatment of patients with progressive PSMA-positive mCRPC and Dr. Morgans’ experience with 177Lu-PSMA-617.
EP. 6: Future Directions and Unmet Needs
Dr. Morgans discusses unmet needs and importance of including multidisciplinary teams when treating patients with mCRPC.
2 Commerce Drive Cranbury, NJ 08512